Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam Inc (BEAT) pioneers portable cardiac monitoring solutions through its credit card-sized ECG device and AI-driven diagnostic platform. This news hub provides investors and healthcare professionals with timely updates on the company’s advancements in remote cardiology technology.
Access authoritative reporting on regulatory milestones, clinical study results, and strategic partnerships shaping the future of telehealth diagnostics. Our curated collection includes earnings reports, product launch announcements, and peer-reviewed research validations, including studies conducted with Harvard Medical School faculty.
Key updates cover developments in Vector ECG technology, FDA clearance progress, and AI algorithm enhancements that improve cardiac event detection accuracy. Bookmark this page to stay informed about innovations bridging hospital-grade diagnostics with at-home healthcare solutions.
HeartBeam, Inc. (NASDAQ: BEAT) has appointed Alan Baumel as the new Chief Operating Officer, a role focused on product development and regulatory affairs for their innovative ECG telemedicine technology. With over 35 years in the medical device sector, Baumel is expected to enhance HeartBeam's commercialization strategy and accelerate FDA product development. His experience includes leadership roles at Bardy Diagnostics and contributions to improving medical device quality and safety. HeartBeam aims to address significant needs in heart attack detection outside medical institutions.
HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed a $16.5 million IPO, selling 2,750,000 units at $6.00 each. The IPO generated net proceeds of $14.9 million, boosting the company’s cash balance to approximately $15.7 million. HeartBeam aims to advance its FDA-ready telemedicine solutions for cardiovascular assessment, with significant milestones set for 2022 and 2023. Q3 2021 financial results show an increased net loss of $1.2 million, up from $335,000 in Q3 2020, while R&D expenses rose to $105,000 from $57,000 year-over-year.
HeartBeam, Inc. (NASDAQ: BEAT) has successfully closed its initial public offering of 2,750,000 units at $6.00 each, generating net proceeds of
HeartBeam, Inc. (NASDAQ: BEAT) has priced its initial public offering of 2,750,000 units at $6.00 per unit, consisting of one share of common stock and one warrant. The offering is expected to generate
Philips has announced its acquisition of BioTelemetry for USD 72.00 per share, totaling an implied enterprise value of USD 2.8 billion. This acquisition aligns with Philips' strategy to enhance healthcare delivery by combining its hospital monitoring capabilities with BioTelemetry’s strengths in remote cardiac diagnostics. BioTelemetry, which reported USD 439 million in sales in 2019, monitors over 1 million cardiac patients annually. The deal is anticipated to yield significant synergies and is expected to be accretive to Philips’ sales growth and adjusted EBITA margin beginning in 2021.
BioTelemetry, Inc. (NASDAQ:BEAT) reported a record quarterly revenue of $114.7 million for Q3 2020, marking a 3.0% year-over-year growth despite COVID-19 challenges. The company achieved a GAAP net income of $6.7 million (or $0.18 per diluted share), down from $8.3 million in Q3 2019. Adjusted net income was $16.5 million ($0.45 per diluted share). The gross profit was $69.0 million, representing 60.2% of total revenue. CEO Joseph H. Capper highlighted growth in all business segments and projected over 15% top-line growth in 2021.
BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2020 earnings on October 29 at 4:00 PM ET. Following this, an earnings conference call will take place at 5:00 PM ET, which will be available via webcast on the investor relations page of their website.
BioTelemetry specializes in remote medical technology, offering services that enhance health information accessibility and lower care costs. Their solutions include remote cardiac monitoring and clinical trial laboratory services.
BioTelemetry, Inc. (NASDAQ: BEAT) has acquired the On.Demand™ remote patient monitoring platform from Envolve People Care, a subsidiary of Centene Corporation. This acquisition enhances BioTelemetry's offerings for chronic care management, specifically targeting diabetes, hypertension, and chronic heart failure. The deal establishes BioTelemetry as the exclusive provider of diabetes RPM services to Centene's Medicaid members. The On.Demand platform aims to improve patient engagement and compliance while reducing healthcare costs through real-time monitoring and coaching.
BioTelemetry, Inc. (NASDAQ: BEAT) will announce its second quarter 2020 earnings on July 30 at 4:00 PM ET, followed by a conference call at 5:00 PM ET. The call will be accessible via the investor section of the BioTelemetry website. The company, a leader in remote medical technology, offers services including remote cardiac monitoring and centralized laboratory services for clinical trials. This announcement may set expectations for the company’s financial performance ahead of the earnings release.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
